Alpha Cognition (Alpha Cognition) Total Current Assets : $2.85 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Alpha Cognition's total current assets for the quarter that ended in Mar. 2024 was $2.85 Mil.

Alpha Cognition Total Current Assets Historical Data

The historical data trend for Alpha Cognition's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Total Current Assets Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Current Assets

7.70

12.17

2.33

1.92

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial										4.03	1.34	1.15	1.92	2.85

Alpha Cognition Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Alpha Cognition's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1.404	+	0.058	+	0	+	0.456
	=	1.92

Alpha Cognition's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.259	+	0	+	0	+	0.595
	=	2.85

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Alpha Cognition (OTCPK:ACOGF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Alpha Cognition's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.259	-	3.296	+	0.75 * 0	+	0.5 * 0
=	-1.04

Alpha Cognition Total Current Assets Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ACOG:Canada

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.